Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Aspirin

Research Leaders

8 sponsors active, led by Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Not Applicable (1)

Trial Status

Recruiting1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT04694248Not ApplicableRecruiting

Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting

NCT03148548CompletedPrimary

Substudy - Evaluation of Patients With Iliac Vein Thrombosis

Showing all 2 trials

Research Network

Common Treatments

  • Aspirin1
  • Rivaroxaban1
  • Thrombophilia Screening1

Active Sponsors

  • Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University1
  • The Central Hospital of Lishui City1
  • Taizhou First People's Hospital1
  • Cardioangiologisches Centrum Bethanien1
  • First Affiliated Hospital of Zhejiang University1

Top Investigators

Related Conditions

  • Deep Vein Thrombosis1
  • Iliac Vein Obstruction1
  • Iliac Vein Compression Syndrome1
  • Iliac Vein Stenosis1

Activity Timeline